BioNTech (BNTX) announced the completion of the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The acquisition was announced on November 2024 and builds on the successful collaboration on the late-stage clinical asset BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, and other bispecific antibody candidates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech Unveils 2025 Strategic Priorities and Pipeline Progress
- BioNTech provides business and pipeline updates
- BioNTech initiated with a Buy at Truist
- NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley
- BioNTech to pay $467M in settlement agreement with University of Pennsylvania